• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

意大利人群对 COVID-19 mRNA 疫苗反应的性别差异。

Sex differences in response to COVID-19 mRNA vaccines in Italian population.

机构信息

Epidemiological Department, Azienda Zero of the Veneto Region, Padua, Italy.

Infectious Diseases Department, Istituto Superiore di Sanità, Rome, Italy.

出版信息

Epidemiol Infect. 2024 Nov 18;152:e139. doi: 10.1017/S0950268824001079.

DOI:10.1017/S0950268824001079
PMID:39552125
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11574602/
Abstract

Since the beginning of mass vaccination campaign for COVID-19 in Italy (December 2020) and following the rapidly increasing vaccine administration, sex differences have been emphasized. Nevertheless, incomplete and frequently incoherent sex-disaggregated data for COVID-19 vaccinations are currently available, and vaccines clinical studies generally do not include sex-specific analyses for safety and efficacy. We looked at sex variations in the COVID-19 vaccine's effectiveness against infection and severe disease outcomes. We conducted a nationwide retrospective cohort study on Italian population, linking information on COVID-19 vaccine administrations obtained through the Italian National Vaccination Registry, with the COVID-19 integrated surveillance system, held by the Istituto Superiore di Sanità. The results showed that, in all age groups, vaccine effectiveness (VE) was higher in the time-interval ≤120 days post-vaccination. In terms of the sex difference in vaccination effectiveness, men and women were protected against serious illness by vaccination in a comparable way, while men were protected against infection to a somewhat greater extent than women. To fully understand the mechanisms underlying the sex difference in vaccine response and its consequences for vaccine effectiveness and development, further research is required. The sex-related analysis of vaccine response may contribute to adjust vaccination strategies, improving overall public health programmes.

摘要

自意大利 2020 年 12 月开始大规模接种 COVID-19 疫苗以来,人们越来越关注性别差异。然而,目前 COVID-19 疫苗接种的性别分类数据不完整且常常不一致,疫苗临床研究通常也不包括安全性和有效性的性别特异性分析。我们研究了 COVID-19 疫苗对感染和严重疾病结果的有效性的性别差异。我们对意大利人群进行了一项全国性回顾性队列研究,将通过意大利国家疫苗接种登记处获得的 COVID-19 疫苗接种信息与由意大利高等卫生研究院持有的 COVID-19 综合监测系统相关联。结果表明,在所有年龄段,接种疫苗后≤120 天的时间间隔内,疫苗有效性(VE)更高。就疫苗有效性的性别差异而言,男性和女性接种疫苗对严重疾病的保护作用相当,而男性对感染的保护作用略高于女性。为了充分了解疫苗反应中性别差异的机制及其对疫苗有效性和开发的影响,需要进一步研究。疫苗反应的性别相关分析可能有助于调整疫苗接种策略,改善整体公共卫生计划。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5e70/11574602/330621942cba/S0950268824001079_fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5e70/11574602/6ab80e962e81/S0950268824001079_fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5e70/11574602/d77fd27f8762/S0950268824001079_fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5e70/11574602/c6cf7fcf4147/S0950268824001079_fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5e70/11574602/330621942cba/S0950268824001079_fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5e70/11574602/6ab80e962e81/S0950268824001079_fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5e70/11574602/d77fd27f8762/S0950268824001079_fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5e70/11574602/c6cf7fcf4147/S0950268824001079_fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5e70/11574602/330621942cba/S0950268824001079_fig4.jpg

相似文献

1
Sex differences in response to COVID-19 mRNA vaccines in Italian population.意大利人群对 COVID-19 mRNA 疫苗反应的性别差异。
Epidemiol Infect. 2024 Nov 18;152:e139. doi: 10.1017/S0950268824001079.
2
Effectiveness against severe COVID-19 of a seasonal booster dose of bivalent (original/Omicron BA.4-5) mRNA vaccines in persons aged ≥60 years: Estimates over calendar time and by time since administration during prevalent circulation of different Omicron subvariants, Italy, 2022-2023.对≥60 岁人群接种二价(原始/Omicron BA.4-5)mRNA 疫苗加强针对严重 COVID-19 的有效性:意大利,2022-2023 年,根据不同 Omicron 亚变体流行期间的日历时间和接种后时间估算
Vaccine. 2024 Oct 3;42(23):126026. doi: 10.1016/j.vaccine.2024.05.074. Epub 2024 Jun 3.
3
COVID-19 Vaccine Effectiveness and Digital Pandemic Surveillance in Germany (eCOV Study): Web Application-Based Prospective Observational Cohort Study.德国 COVID-19 疫苗有效性和数字大流行监测(eCOV 研究):基于网络应用的前瞻性观察队列研究。
J Med Internet Res. 2024 Jun 4;26:e47070. doi: 10.2196/47070.
4
COVID-19 vaccine effectiveness against hospitalizations in Paraguay, May 2021-April 2022: A test-negative design.2021 年 5 月至 2022 年 4 月巴拉圭的 COVID-19 疫苗对住院的有效性:一项似然比检验设计。
Vaccine. 2023 Oct 13;41(43):6453-6460. doi: 10.1016/j.vaccine.2023.09.015. Epub 2023 Sep 15.
5
Vaccine effectiveness in reducing COVID-19-related hospitalization after a risk-age-based mass vaccination program in a Chilean municipality: A comparison of observational study designs.基于风险年龄的大规模疫苗接种计划后降低智利市与 COVID-19 相关的住院率的疫苗有效性:观察性研究设计的比较。
Vaccine. 2024 Jul 11;42(18):3851-3856. doi: 10.1016/j.vaccine.2024.05.002. Epub 2024 May 15.
6
Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data.以色列全国疫苗接种运动后,mRNA BNT162b2疫苗对SARS-CoV-2感染及COVID-19病例、住院和死亡的影响与效果:一项利用国家监测数据的观察性研究
Lancet. 2021 May 15;397(10287):1819-1829. doi: 10.1016/S0140-6736(21)00947-8. Epub 2021 May 5.
7
Effectiveness of mRNA vaccines and waning of protection against SARS-CoV-2 infection and severe covid-19 during predominant circulation of the delta variant in Italy: retrospective cohort study.在意大利德尔塔变异株流行期间,mRNA 疫苗对 SARS-CoV-2 感染和重症 COVID-19 的有效性及其保护作用的衰减:回顾性队列研究。
BMJ. 2022 Feb 10;376:e069052. doi: 10.1136/bmj-2021-069052.
8
Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance - VISION Network, 10 States, August 2021-January 2022.在德尔塔和奥密克戎变异株流行期间,mRNA 疫苗加强针在成年人中的 COVID-19 相关急诊和紧急护理就诊和住院方面的效果 - VISION 网络,10 个州,2021 年 8 月至 2022 年 1 月。
MMWR Morb Mortal Wkly Rep. 2022 Jan 21;71(4):139-145. doi: 10.15585/mmwr.mm7104e3.
9
Dynamic IgG seropositivity after rollout of CoronaVac and BNT162b2 COVID-19 vaccines in Chile: a sentinel surveillance study.智利科兴和国药疫苗接种后动态 IgG 血清阳性率:哨点监测研究。
Lancet Infect Dis. 2022 Jan;22(1):56-63. doi: 10.1016/S1473-3099(21)00479-5. Epub 2021 Sep 9.
10
Effectiveness of two and three doses of COVID-19 mRNA vaccines against infection, symptoms, and severity in the pre-omicron era: A time-dependent gradient.两种和三种剂量的 COVID-19 mRNA 疫苗在奥密克戎时代前针对感染、症状和严重程度的有效性:时间依赖性梯度。
Vaccine. 2024 May 22;42(14):3307-3320. doi: 10.1016/j.vaccine.2024.04.026. Epub 2024 Apr 14.

引用本文的文献

1
An mRNA Vaccine Expressing Blood-Stage Malaria Antigens Induces Complete Protection Against Lethal .一种表达血液期疟疾抗原的信使核糖核酸疫苗可诱导对致死性疟疾的完全保护。
Vaccines (Basel). 2025 Jun 28;13(7):702. doi: 10.3390/vaccines13070702.

本文引用的文献

1
COVID-19 Vaccination Actual Uptake and Potential Inequalities Due to Socio-Demographic Characteristics: A Population-Based Study in the Umbria Region, Italy.新冠病毒疫苗接种的实际接种率及因社会人口特征导致的潜在不平等:意大利翁布里亚地区的一项基于人群的研究
Vaccines (Basel). 2023 Aug 9;11(8):1351. doi: 10.3390/vaccines11081351.
2
Determinants of COVID-19 vaccination acceptance or hesitancy in Italy: an overview of the current evidence.意大利人对 COVID-19 疫苗接种的接受或犹豫的决定因素:当前证据概述。
Ann Ist Super Sanita. 2023 Jan-Mar;59(1):10-25. doi: 10.4415/ANN_23_01_03.
3
COVID-19 vaccines: Considering sex differences in efficacy and safety.
新冠疫苗:考虑疗效和安全性方面的性别差异。
Contemp Clin Trials. 2022 Apr;115:106700. doi: 10.1016/j.cct.2022.106700. Epub 2022 Feb 8.
4
Effectiveness of mRNA vaccines and waning of protection against SARS-CoV-2 infection and severe covid-19 during predominant circulation of the delta variant in Italy: retrospective cohort study.在意大利德尔塔变异株流行期间,mRNA 疫苗对 SARS-CoV-2 感染和重症 COVID-19 的有效性及其保护作用的衰减:回顾性队列研究。
BMJ. 2022 Feb 10;376:e069052. doi: 10.1136/bmj-2021-069052.
5
Italy's rollout of COVID-19 vaccinations: The crucial contribution of the first experimental mass vaccination site in Lombardy.意大利新冠疫苗的推广:伦巴第首个大规模疫苗试验接种点的关键贡献。
Vaccine. 2022 Mar 1;40(10):1397-1403. doi: 10.1016/j.vaccine.2022.01.059. Epub 2022 Feb 3.
6
COVID-19 Vaccination Coverage and Vaccine Confidence by Sexual Orientation and Gender Identity - United States, August 29-October 30, 2021.COVID-19 疫苗接种覆盖率和性取向及性别认同疫苗信心-美国,2021 年 8 月 29 日至 10 月 30 日。
MMWR Morb Mortal Wkly Rep. 2022 Feb 4;71(5):171-176. doi: 10.15585/mmwr.mm7105a3.
7
A Systematic Review of the Sex and Gender Reporting in COVID-19 Clinical Trials.COVID-19 临床试验中性别与性别的报告的系统评价
Vaccines (Basel). 2021 Nov 15;9(11):1322. doi: 10.3390/vaccines9111322.
8
Sex and Gender in COVID-19 Vaccine Research: Substantial Evidence Gaps Remain.新冠疫苗研究中的性别与性:重大证据空白依然存在。
Front Glob Womens Health. 2021 Nov 1;2:761511. doi: 10.3389/fgwh.2021.761511. eCollection 2021.
9
Sex Disparities in Efficacy in COVID-19 Vaccines: A Systematic Review and Meta-Analysis.新冠疫苗效力的性别差异:一项系统评价与荟萃分析
Vaccines (Basel). 2021 Jul 27;9(8):825. doi: 10.3390/vaccines9080825.
10
Sex differences in the case-fatality rates for COVID-19-A comparison of the age-related differences and consistency over seven countries.COVID-19 病死率的性别差异-比较七个国家的年龄相关差异和一致性。
PLoS One. 2021 Apr 29;16(4):e0250523. doi: 10.1371/journal.pone.0250523. eCollection 2021.